These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 24928186)

  • 1. Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.
    Einersen P; Epelboym I; Winner MD; Leung D; Chabot JA; Allendorf JD
    J Gastrointest Surg; 2014 Aug; 18(8):1441-4. PubMed ID: 24928186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.
    Kim MJ; Lee KH; Lee KT; Lee JK; Ku BH; Oh CR; Heo JS; Choi SH; Choi DW
    Pancreas; 2012 Aug; 41(6):897-903. PubMed ID: 22699202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure ground glass nodular adenocarcinomas: Are preoperative positron emission tomography/computed tomography and brain magnetic resonance imaging useful or necessary?
    Cho H; Lee HY; Kim J; Kim HK; Choi JY; Um SW; Lee KS
    J Thorac Cardiovasc Surg; 2015 Sep; 150(3):514-20. PubMed ID: 26189165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between apparent diffusion coefficients on diffusion-weighted MRI and standardized uptake value on FDG-PET/CT in pancreatic adenocarcinoma.
    Sakane M; Tatsumi M; Kim T; Hori M; Onishi H; Nakamoto A; Eguchi H; Nagano H; Wakasa K; Hatazawa J; Tomiyama N
    Acta Radiol; 2015 Sep; 56(9):1034-41. PubMed ID: 25267921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
    Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
    AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
    Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
    Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.
    Heinrich S; Goerres GW; Schäfer M; Sagmeister M; Bauerfeind P; Pestalozzi BC; Hany TF; von Schulthess GK; Clavien PA
    Ann Surg; 2005 Aug; 242(2):235-43. PubMed ID: 16041214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging chest computed tomography and positron emission tomography in patients with pancreatic adenocarcinoma: utility or futility?
    Pappas SG; Christians KK; Tolat PP; Mautz AP; Lal A; McElroy L; Gamblin TC; Turaga KK; Tsai S; Erickson B; Ritch P; Evans DB
    HPB (Oxford); 2014 Jan; 16(1):70-4. PubMed ID: 23496023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
    Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
    Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study.
    Buchs NC; Bühler L; Bucher P; Willi JP; Frossard JL; Roth AD; Addeo P; Rosset A; Terraz S; Becker CD; Ratib O; Morel P
    J Gastroenterol Hepatol; 2011 Apr; 26(4):657-62. PubMed ID: 21155879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.